ストックスクリーナーアプリを入手
4.46
1.11%
-0.05
アフターアワーズ：
4.64
0.18
+4.04%
前日終値:
$4.51
開ける：
$4.44
24時間の取引高:
43,115
Relative Volume:
0.13
時価総額：
$6.50M
収益：
$12.99M
当期純損益:
$-23.72M
株価収益率:
-0.0459
EPS:
-97.2514
ネットキャッシュフロー:
$-23.28M
1週間 パフォーマンス:
-6.89%
1か月 パフォーマンス:
+6.19%
6か月 パフォーマンス:
-79.25%
1年 パフォーマンス:
-98.24%
1日の値動き範囲:
$4.38
$4.75
1週間の範囲:
$4.30
$4.79
52週間の値動き範囲:
$3.65
$399.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
APVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.46 | 6.50M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - AccessWire
Aptevo's Senior Director to Present ADAPTIR Platform at Major Biotech Conference PepTalk 2025 - StockTitan
Trend Tracker for (APVO) - Stock Traders Daily
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year? - Yahoo Finance
Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish - MSN
APVO stock touches 52-week low at $5.1 amid sharp annual decline - Investing.com Australia
Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial - Marketscreener.com
Aptevo reports full remission in AML trial - Investing.com India
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - AccessWire
Aptevo reports full remission in AML trial By Investing.com - Investing.com UK
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - AccessWire
Aptevo's AML Drug Trial Hits 100% Remission Rate, Complete Cancer Cell Elimination in Phase 1b Study - StockTitan
(APVO) On The My Stocks Page - Stock Traders Daily
Aptevo Therapeutics executes reverse stock split - Investing.com India
Aptevo Therapeutics executes reverse stock split By Investing.com - Investing.com Australia
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - AccessWire
Aptevo's Novel Prostate Cancer Therapy Shows Promise in Preclinical Studies, Targets $24B Market - StockTitan
Sweden’s Alligator Makes Cuts To Avoid Extinction - News & Insights
Alligator Bioscience completes a rights issue of SEK 280 million - Marketscreener.com
Alligator Bioscience to make a rights issue of units of SEK 199 million - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split By Investing.com - Investing.com Nigeria
Stock Market Movers Today • Top Gainers & Losers - Benzinga
What's Going On With Aptevo Therapeutics Shares Friday? - Benzinga
Aptevo Therapeutics Announces 1-for-37 Reverse Stock Split - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split - Investing.com
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - AccessWire
Aptevo Therapeutics Announces 37-to-1 Reverse Split to Meet Nasdaq Requirements | APVO Stock News - StockTitan
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - AccessWire
Aptevo to Showcase Cancer Therapy Platform at Major Healthcare Conference | APVO Stock News - StockTitan
Does Aptevo Therapeutics Inc (NASDAQ: APVO) Still Look Hot This Week? - Stocks Register
Aptevo reports progress in cancer antibody trials By Investing.com - Investing.com Australia
Aptevo reports progress in cancer antibody trials - Investing.com India
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - AccessWire
Aptevo's Cancer Drug Shows 90% Blast Reduction in AML Trial, Pipeline Advances | APVO Stock News - StockTitan
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - AccessWire
Aptevo's AML Drug Shows 90% Cancer Reduction in Early Trial Results | APVO Stock News - StockTitan
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com - Defense World
Armistice Capital, LLC's Strategic Acquisition of Aptevo Therape - GuruFocus.com
Alligator Bioscience reports positive results for APV-527 in Phase 1 study - Marketscreener.com
Alligator Bioscience announces positive results for APV-527 - Marketscreener.com
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - AccessWire
Aptevo's Cancer Drug Shows Promise: 56% of Patients Achieve Disease Stability in Phase 1 | APVO Stock News - StockTitan
Hudson Bay Capital Management LP's Strategic Acquisition in Apte - GuruFocus.com
Aptevo Therapeutics Inc (APVO) Quarterly 10-Q Report - Quartz
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - AccessWire
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):